Evidence map›Paper›PMID 24091848›Full record

ArticleLeukemia2014

In vitro generation of mature, naive antigen-specific CD8(+) T cells with a single T-cell receptor by agonist selection.

S Snauwaert, G Verstichel, S Bonte, G Goetgeluk, S Vanhee, Y Van Caeneghem, K De Mulder, C Heirman, H Stauss, M H M Heemskerk and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Generation ofHeliyon · 2024
    Article
  3. Mucosal-associated invariant T cells for cancer immunotherapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2023
    Review
  4. Review
  5. Review
  6. Oncoimmunology · 2021
    Article
  7. Review
  8. Article
  9. Article
  10. Applications of molecular engineering in T-cell-based immunotherapies.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2019
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 3 countries.

S SnauwaertDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium.
G VerstichelDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium.
S BonteDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium.
G GoetgelukDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium.
S VanheeDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium.
Y Van CaeneghemDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium.
K De MulderDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium.
C HeirmanLaboratory of Molecular & Cellular Therapy of the Department of Physiology and Immunology, Free University Brussels (VUB), Brussels, Belgium.
H StaussDepartment of Immunology, University College London, London, UK.
M H M HeemskerkLaboratory of Experimental Hematology of the Department of Hematology, Leids Universitair Medisch Centrum, Leiden, The Netherlands.
T TaghonDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium.
G LeclercqDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium.
J PlumDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium.
A W LangerakDepartment of Immunology, Erasmus Medical Center, Rotterdam, The Netherlands.
K ThielemansLaboratory of Molecular & Cellular Therapy of the Department of Physiology and Immunology, Free University Brussels (VUB), Brussels, Belgium.
T KerreDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium.
B VandekerckhoveDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium.
Ghent University Hospital · BEGhent University · BEErasmus MC · NLLeiden University Medical Center · NLUniversity College London · GB

Funding

Medical Research Council G0900950
6 · The paper itself

Abstract

Peripheral blood T cells transduced with a tumor-specific T-cell receptor (TCR) face problems of auto-reactivity and lack of efficacy caused by cross-pairing of exogenous and endogenous TCR chains, as well as short term in vivo survival due to activation and growth factor-induced differentiation. We here studied an alternative strategy for the efficient generation of naive CD8(+) T cells with a single TCR. TCR-transduced human postnatal thymus-derived and adult mobilized blood-derived hematopoietic progenitor cells (HPCs) were differentiated to CD4(+)CD8(+) double-positive T cells using OP9-Delta-like 1 (OP9-DL1) cultures. Addition of the agonist peptide induced double positive cells to cross-present the peptide, leading, in the absence of co-stimulation, to cell cycle arrest and differentiation into mature CD8(+) T cells. Comprehensive phenotypic, molecular and functional analysis revealed the generation of naive and resting CD8(+) T cells through a process similar to thymic positive selection. These mature T cells show a near complete inhibition of endogenous TCRA and TCRB rearrangements and express high levels of the introduced multimer-reactive TCR. Upon activation, specific cytokine production and efficient killing of tumor cells were induced. Using this strategy, large numbers of high-avidity tumor-specific naive T cells can be generated from readily available HPCs without TCR chain cross-pairing.

Indexed as

AdultCD8-Positive T-LymphocytesCell DifferentiationCell Line, TumorChildChild, PreschoolGene Rearrangement, T-LymphocyteHumansImmunotherapy, AdoptiveInfantInfant, NewbornReceptors, Antigen, T-CellReceptors, Antigen, T-Cell

Identifiers

PMID24091848
OpenAlexW2090511271

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.